PROK Overview

Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.

Wall Street analysts forecast PROK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PROK is5.33 USD with a low forecast of 1.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Prokidney Corp revenue for the last quarter amounts to 225.00K USD, increased 196.05

Prokidney Corp. EPS for the last quarter amounts to -0.14 USD, decreased -17.65

Prokidney Corp (PROK) has 231 emplpoyees as of March 29 2026.

Today PROK has the market capitalization of 481.34M USD.